Tamoxifen (antiestrogen) therapy in advanced breast cancer

Ann Intern Med. 1977 Dec;87(6):687-90. doi: 10.7326/0003-4819-87-6-687.

Abstract

Fifty-nine postmenopausal women with advanced breast cancer were treated with tamoxifen (antiestrogen), 20 mg orally twice a day for at least 2 months. They had been previously treated with other types of hormonal therapy or intensive chemotherapies, or both. Nineteen of the 59 patients (32%) had either a complete response (seven patients) or partial response (12 patients). The median duration of response was 9+ months. Tumors containing estrogen receptors and those that responded to previous hormonal manipulation tended to respond to tamoxifen (60% and 69%, respectively). Patients with receptor-negative tumor or with a history of failure of previous hormonal treatments did not respond to tamoxifen therapy. Tamoxifen is effective against advanced breast cancer. Side effects of the treatment were mild.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Estradiol / blood
  • Estrone / blood
  • Female
  • Humans
  • Menopause
  • Middle Aged
  • Neoplasm Metastasis
  • Prolactin / blood
  • Receptors, Estrogen
  • Tamoxifen / adverse effects
  • Tamoxifen / therapeutic use*

Substances

  • Receptors, Estrogen
  • Tamoxifen
  • Estrone
  • Estradiol
  • Prolactin